Merck & Co., Inc. (MRK)
| Market Cap | 369.90B +70.2% |
| Revenue (ttm) | 67.38B +4.9% |
| Net Income | 2.45B -87.1% |
| EPS | 0.99 -86.9% |
| Shares Out | 2.47B |
| PE Ratio | 151.63 |
| Forward PE | 17.42 |
| Dividend | $3.40 (2.27%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 5,338,248 |
| Open | 149.55 |
| Previous Close | 146.33 |
| Day's Range | 147.40 - 151.35 |
| 52-Week Range | 82.01 - 156.92 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 159.60 (+6.45%) |
| Earnings Date | Oct 29, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $159.6, which is an increase of 6.45% from the latest price.
News
Merck price target lowered to $174 from $177 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Merck (MRK) to $174 from $177 and keeps an Overweight rating on the shares.
Merck price target raised to $175 from $165 at JPMorgan
JPMorgan raised the firm’s price target on Merck (MRK) to $175 from $165 and keeps an Overweight rating on the shares.
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today re...
Merck price target raised to $171 from $170 at Guggenheim
Guggenheim raised the firm’s price target on Merck (MRK) to $171 from $170 and keeps a Buy rating on the shares after updating the firm’s model following the company’s Q3…
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Merck & Co., Inc. ("Merck" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is inve...
Merck & Co. Earnings Call Transcript: Q3 2026
Q3 revenue rose 5% to $18.1B, with new products and oncology and animal health strength. 2026 guidance midpoint increased; 2027 is expected to bring moderate growth amid >$2B of generic and LOE headwinds and continued investment.
Merck & Co. Earnings release: Q3 2026
Merck & Co. released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Merck & Co. Prepared remarks: Q3 2026
Merck & Co. filed a regulatory document on October 29, 2026 disclosing important business information.
Merck & Co. Slides: Q3 2026
Merck & Co. has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Merck Stock (MRK) Rises 2% on $830 Million Keytruda Sales Beat, Q3 Forecasts, and Higher Full-Year Profit Outlook
Merck & Co ($MRK) shares rose 2.14% in Thursday premarket trading after the drugmaker beat third-quarter Wall Street estimates and raised its full-year adjusted profit forecast. Strong demand for its…
Merck Revenue Up on Keytruda, Winrevair Growth
Third-quarter profit came in at $5.07 billion, or $2.04 a share, compared with $5.79 billion, or $2.32 a share, a year earlier.
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck topped third-quarter estimates and hiked its adjusted profit outlook. The company's immunotherapy Keytruda, including a newer injectable form of the drug called Qlex, posted stronger-than-expect...
Merck Earnings Blow Past Estimates. Why Wall Street Is Looking Past the Numbers.
Merck is leaning on newer drugs and the promise of its pipeline assets as a patent cliff looms for its largest revenue driver, Keytruda.
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline.
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
Merck & Co. Transcript: Investor update
TroFuse-005 showed significant PFS, OS and response gains for sac-TMT in advanced or recurrent endometrial cancer. INTerpath-001 delivered positive phase III results for individualized neoantigen therapy in melanoma, while MK-2010 phase III studies are anticipated in H1 2027.
Merck & Co. Slides: Investor update
Merck & Co. has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Merck & Co. Press release: Investor update
Merck & Co. issued a press release on October 26, 2026, disclosing material business information to investors.
Data about Merck and Moderna Melanoma Vaccine Leaks Out
Leaked data from Moderna and Merck's highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Norm...
Merck says Keytruda reduced risk of disease progression in endometrial cancer
Merck (MRK) announced the first presentation of results from the Phase 3 KEYNOTE-C93 trial, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with mismatch r...
Merck's therapy extends survival in hard-to-treat uterine cancer patients
Merck's experimental targeted drug helped women with advanced endometrial cancer live longer and kept their disease in check compared with standard treatment, according to late-stage trial data
Merck reports sac-TMT reduced risk of death by 32% in TroFuse-005 trial
Merck (MRK) announced the first presentation of results from the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan, or sac-TMT, an investigational TROP2-directed antibody-drug conju...
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Sac-TMT Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in TroFuse-005 Trial.
Moderna price target raised to $230 from $167 at Piper Sandler
Piper Sandler raised the firm’s price target on Moderna to $230 from $167 and keeps an Overweight rating on the shares. The firm notes Moderna (MRNA) and partner Merck (MRK)…
Merck price target raised to $180 from $150 at Barclays
Barclays raised the firm’s price target on Merck (MRK) to $180 from $150 and keeps an Overweight rating on the shares. The firm says the full intismeran data reinforced the…